Galera Therapeutics (GRTX) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Galera Therapeutics (NASDAQ: GRTX) recently:

  • 12/2/2019 – Galera Therapeutics is now covered by analysts at Credit Suisse Group AG. They set a “neutral” rating and a $14.00 price target on the stock.
  • 12/2/2019 – Galera Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $30.00 price target on the stock.
  • 12/2/2019 – Galera Therapeutics is now covered by analysts at Citigroup Inc. They set a “buy” rating and a $20.00 price target on the stock.
  • 12/2/2019 – Galera Therapeutics is now covered by analysts at Bank of America Corp. They set a “buy” rating and a $15.00 price target on the stock.

Shares of Galera Therapeutics stock opened at $10.00 on Tuesday. Galera Therapeutics has a one year low of $9.26 and a one year high of $14.88.

In other news, insider Holdings A/S Novo bought 500,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average price of $12.76 per share, with a total value of $6,380,000.00. Also, major shareholder Enterprise Associates 14 New purchased 416,666 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of $11.79 per share, for a total transaction of $4,912,492.14.

Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.

See Also: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.